Podcasts about Cart

This week, we discuss a promising step toward a functional cure for chronic hepatitis B, first-line pulsed field ablation for persistent atrial fibrillation, reducing the demand for transfusion in surgery, treatment for rifampicin-resistant tuberculosis, and a decade-long look at CAR T-cell therapy outcomes. We review peanut allergy and discuss a case of a man with leg weakness, pain, and weight loss; Perspectives explore GLP-1 access, air-quality policy, and the human realities of homelessness.

In this episode of Case Studies, Casey back sits down with Doug Cartwright; entrepreneur, author, speaker, and longtime friend; for one of the most personal and powerful conversations ever shared on the show. After being diagnosed with stage 4 glioblastoma, an aggressive and incurable form of brain cancer, Doug opens up about the months leading to his diagnosis, the emotional weight of confronting mortality, and the perspective shift that followed. Together, they explore faith, friendship, resilience, and the surprising gifts that can emerge from life's most difficult challenges. Doug shares how his relationship with God has deepened, why relationships have become his highest priority, and how a renewed sense of urgency has sharpened his appreciation for everyday moments. He also discusses the cutting edge treatment options he is pursuing, including a groundbreaking CAR-T clinical trial at the University of Pennsylvania, and the resourcefulness required to keep fighting when the odds are stacked against him. Doug's perspective is a powerful reminder that life's greatest challenges often reveal what matters most.To support Doug's treatment, medical expenses, and clinical trial journey, you can donate here: gofund.me/0ef9a2dae Hosted on Acast. See acast.com/privacy for more information.

AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the takeout and the assets AbbVie gains.The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency's former leadership and assess Acting CDER Director Michael Davis' memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA.Finally, they discuss China NMPA's first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen.View full story: https://www.biocentury.com/article/659864#BiotechMA #Immunology #FDA #CART #ChinaBiotech00:59 - AbbVie Buys Apogee05:20 - uniQure U-turn09:02 - FDA Reversals12:32 - Tzield Memo20:53 - Solid Tumor CAR T ApprovalTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

This month, the gals keep the trend going and welcome Cory back to the stage (from the dining room) to discuss Canadian liberty, long drops, a different kind of catnip, transit disasters, mummy sourdough, and geocaching in the afterlife. Tune in for the June episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

Making CAR-T cells from donor bone marrow already used to treat someone's cancer helped rein in cancer recurrence, a new study shows. Kimmel Cancer Center director William Nelson at Johns Hopkins says this is one more place where an expansion … Can a new method for developing CAR-T cells to treat cancer be expanded? Elizabeth Tracey reports Read More »

Specially engineered T cells, one component of immune cells in your body, are called CAR-T cells, and for several years now have been used to treat blood cancers and some other conditions, with some success. William Nelson, director of the … Are CAR-T cells coming into their own as therapeutic agents? Elizabeth Tracey reports Read More »

CAR-T cells developed from bone marrow donors whose bone marrow had already been used to treat someone's cancer may be able to rein in cancer recurrence, a new study finds. Johns Hopkins Kimmel Cancer Center director William Nelson says this … Can donor CAR-T cells have an impact on cancer treatment? Elizabeth Tracey reports Read More »

Hoy hablamos de esos fanáticos que aparecen cuando su equipo gana o cuando hay una gran noticia deportiva, pero de repente se creen analistas sin conocer realmente del deporte. Debatimos sobre la pasión real, los seguidores de moda y la diferencia entre apoyar y fingir ser experto.See omnystudio.com/listener for privacy information.

In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.

Explore the rapidly evolving world of CAR T-cell therapy and how scientists are reengineering the immune system to fight disease. Drs. David Wald and Reshmi Parameswaran discuss breakthroughs in cancer immunotherapy, including faster manufacturing, next‑generation CAR T-cell design, and efforts to expand these therapies from blood cancers to solid tumors and autoimmune diseases. This conversation highlights the promise and challenges of bringing these innovative treatments to patients. Learn more about Daniel Simon, MD Learn more about David Wald, MD, PhD Learn more about Reshmi Parameswaran, PhD, MS View our Science@UH video podcast on YouTubeLearn more about the University Hospitals Research & Education Institute

Y'a t'il une norme en matière d'amour ? Y'a t'il un moule dans lequel on doit se fondre, un modèle à suivre, un idéal à atteindre ? Si vous êtes fidèles à ce podcast vous savez bien que non. Alors quand il s'agit de différence d'âge, pourquoi porte-t-on ce regard critique ? Pourquoi ces «elle cherche son père» «il a besoin d'une mère» «il prend une jeunette parce qu'il ne veut pas vieillir» ? Caroline y a bien pensé à toutes ses phrases.. mais quand l'amour est là, vous le savez maintenant, plus aucun cliché ne compte, évidemment.[REDIFF]

L'émission 28 minutes du 16/06/2026 Nucléaire iranien enrichi : menace écartée ou danger reporté ? Un protocole d'accord entre l'Iran et les États-Unis a été signé le 15 juin après presque quatre mois de guerre. L'accord lui-même doit être signé le 19 juin. Ils auront ensuite 60 jours pour sceller un accord définitif, notamment sur le programme nucléaire iranien et les stocks d'uranium enrichi. L'Iran détient plus de 440 kilos d'uranium enrichi à 60 %, au-dessus des normes civiles et proche des 90 % nécessaires pour la fabrication de la bombe atomique. Donald Trump a affirmé le 13 juin vouloir récupérer l'uranium enrichi “le moment venu”. L'Agence internationale de  l'énergie atomique a demandé à plusieurs reprises l'accès à ces sites, qui lui ont été déclinés. On en débat avec Emmanuelle Galichet, enseignante-chercheuse en sciences et technologies nucléaires au CNAM, Bernard Hourcade, géographe, directeur de recherche au CNRS, spécialiste de l'Iran et Maneli Mirkhan, experte en relations internationales et spécialiste de l'Iran.  28 minutes est le magazine d'actualité d'ARTE, présenté par Élisabeth Quin du lundi au jeudi à 20h05. Renaud Dély est aux commandes de l'émission le vendredi et le samedi. Ce podcast est coproduit par KM et ARTE Radio. Enregistrement 16 juin 2026 Présentation Élisabeth Quin Production KM, ARTE Radio

LikeFolio's Andy Swan is bullish on DoorDash (DASH), citing strong consumer demand that continues to outpace Uber Technologies (UBER) and Maplebear's (CART) Instacart. He says investments in AI, automation, and delivery tech position the company for long-term growth despite short-term profit concerns.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

A leading New Zealand research institute believes it is on track to deliver a cutting edge immunotherapy for blood cancer patients in the public system next year. But only if it can get government funding. Researchers at the Malaghan Institute are well into clinical trials of CAR-T cell therapy with 60 patients. The institute's Clinical Director, Doctor Robert Weinkove spoke to Lisa Owen.

REDIFF - Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.fr.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Tara Gregory, MD, Colorado Blood Cancer Institute, Denver, CO and Jay Spiegel, MD, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 28, 2026 Tara Gregory, MD President Colorado Blood Cancer Institute Denver, CO Jay Spiegel, MD Assistant Professor Division of Transplant and Cellular Therapy University of Miami Sylvester Comprehensive Cancer Center Miami, FL In this episode, Dr. Tara Gregory from the Colorado Blood Cancer Institute, and Dr. Jay Spiegel from the Sylvester Comprehensive Cancer Center discuss the evolving role of CAR T-cell therapy in lymphoma and myeloma. They provide a practical overview of CAR-T, including currently approved indications, importance of early referral, patient selection considerations, and strategies for engaging patients in treatment discussions. The conversation also covers key aspects of toxicity management and post-treatment monitoring, while addressing current limitations of CAR-T therapy and future directions that may further expand its role in patient care. Tune in today for this exciting episode! Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients This episode is supported by Bristol Myers Squibb, Johnson & Johnson & Legend Biotech, and Kite, a Gilead Company.

Tracy is here and making us laugh from the jump. Go Knicks, and go Bravo and Cocktails - because we're both having big weeks. Cocktailers knew that Jennifer Lawrence was the one who helped Andy figure out who recorded the audio leak from the Summer House reunion. Lots of people laughed about this and didn't believe us. But we were right. It was confirmed by Zaddy Andy himself - and have details about how it all went down. Tracy is Adding Kyle Cooke to her cart. Jesse Solomon has worked his way (back) into our hearts. Are we all buying into Amanda's damsel in distress act? Nope...co-host Amanda has some strongly worded thoughts on this. We've got intel on the new Summer House cast...and a theory that you're not hearing anywhere else. Tracy's thoughts on In the City...and what we're seeing for the first time on Bravo. And egg freezing ... why it can be life changing.    This week's episode of Cocktails and Gossip is brought to you by our sponsors:  -Nutrafol: See visibly thicker, stronger, faster grwing hair in 3-6 months with Nutrafol. Cocktailers get $10 off your first month's subscription and free shipping when you visit Nutrafol.com and enter promo code GOSSIP. -Article: Article is offering Cocktailers $50 off your first purchase of $100 or more. To claim, visit https://www.article.com/discount/gossip and the discount will be automatically applied at checkout.  

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Full show notes: https://bengreenfieldlife.com/dralbert In this episode, Dr. Pradeep Albert breaks down the science behind HarmonIQ, formerly Hapbee, a wearable wellness company using frequency-based technology to help you access specific physiological states on demand, from deeper sleep and sharper focus to stress reduction and addiction support, all without ingesting anything. This episode also marks the official launch of HarmonIQ and its new pet-focused line Hapbee Pets. You'll discover why quality sleep without pills is the non-negotiable foundation on which every advanced longevity therapy sits, what Dezawa MuseCells are doing to cartilage and bone in professional athletes who would otherwise be facing surgery, and where CAR T-cell therapy is headed over the next decade. You'll also gain insights into peptide stacks including LL-37, ipamorelin, tessamorelin, MOTS-c, PT-141, cerebrolysin, and GHK-Cu, and what the recent FDA reclassification of 14 peptides back to Category 1 means for anyone currently using or considering them. Dr. Pradeep Albert, MD, DABR, is a board-certified musculoskeletal radiologist, author, and internationally recognized thought leader in regenerative medicine and longevity science. Over three decades, he has performed thousands of regenerative procedures, treated professional athletes across the NFL, MLB, NBA, and NHL, published over 50 peer-reviewed articles, and shaped peptide and stem cell legislation across multiple countries including advising heads of state on healthcare policy. He is the CEO of Vesalius Longevity Labs, founder of the American Academy of Peptide Medicine, and creator of RadSherpa, an AI-powered diagnostic platform now deployed in 89 countries. Save $50 on your HarmonIQ Limitless Neckband and Hapbee Pets Pad (discount auto-applied). Episode Sponsors Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website). Young Goose: To experience the transformative power of Young Goose's cutting-edge skincare products, visit younggoose.com and use code BGF10 at checkout to enjoy a 10% discount on your order. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io. Pendulum: Metabolic Daily is a powerful multi-strain probiotic that improves your metabolism, reduces sugar cravings, breaks down carbs more efficiently, and sustains your energy levels. You’ll receive 20% off your first month of any Pendulum probiotic with code BEN at PendulumLife.com.See omnystudio.com/listener for privacy information.

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

“I wanna hear THAT at my grocery store, when I'm going for the meat section…”   Whether it's the song we all rise for at sports ball events,  the first song on Rush's “Fly By Night” album (not to mention the first song on Anthrax's EP of classic rock covers), or the sing-along, encore at the end of a rock show, ANTHEMS represent a clarion call, a rallying cry that unites fans in unspeakable joy, unity, and celebration. It's almost always the song that EVERYONE knows (even your grandmother) and is very much NOT a deep cut.    “AC/DC's kind of an anthem band…they have at least one on every album…”   In fact, ANTHEMS are those kinds of songs where, if you hear one in a public place: at a bar, a restaurant, the grocery store, or a friend's party, you're not going to NOT like it. Sure, it's probably the most well-known, popular, played into the ground, mainstream “hit” that EVERYONE (again, probably even your grandmother) is familiar with, but no matter what song it is or where you might hear it, ANTHEMS are  guaranteed to get you fired up, lift your spirit, and bring a smile to your face.   “I wanna do a little birthday squig…”   Find out what's happening “THIS FRIDAY”, realize that birthdays are the anniversaries of life, and JOIN US for a Bunkerpoon birthday celebration full of cake, refreshments, and good cheer as we cuss and discuss the unifying power behind rock and metal ANTHEMS. Visit www.metalnerdery.com/podcast for more on this episode Help Support Metal Nerdery https://www.patreon.com/metalnerderypodcast Leave us a Voicemail to be played on a future episode: 980-666-8182 Metal Nerdery Tees and Hoodies – metalnerdery.com/merch and kindly leave us a review and/or rating on your favorite Podcast app Follow us on the Socials: Facebook - Instagram - TikTok Email: metalnerdery@gmail.com Can't be LOUD Enough Playlist on Spotify Metal Nerdery Munchies on YouTube @metalnerderypodcast   Show Notes: (00:01): “I think I just turned it up…”/ “I'm upright and taking nourishment…”/  “I'll give myself the bean…”/ “I'll put it wherever you want…you want it on the inside or the outside?” / ***WARNING: #listenerdiscretionisadvised *** / #keepitthrashy / “Maybe he just unlocked another dimension with his weed…”/ “Dr. Pepper, Captain Morgan, and PB&J's…”/ #yeah / #McDonalds #DirtyDrPepper #Rim / “Was the rim the best part?” / “If you have foam down there, you should really go see your doctor…to have him finish you to completion…”/ ***WELCOME BACK TO THE METAL NERDERY PODCAST AND THE BUNKERPOON CENTER FOR METAL EXCELLENCE!!!*** / #happybirthday / #birthdayepisode / “I eat once a day…I'm the lightest I've been in 3 years…”/ “A handful of food, 5 times a day…”/ #cavemandiet / “Fasting is the way…”/ “Now they're saying that sugar is WORSE than heroin…”/ “It's all mental…” (07:37): ***PATREON US at patreon.com/metalnerderypodcast *** / #SpiritInTheSky /  “I was looking at the name: I thought it said ‘My Boss'…”/ ***SOCIAL MEDIA US at #MetalNerderyPodcast on #YouTube #Facebook #InstaGram and #TikTok *** / #drysockets and #wisdomteeth #viralaf / #Pyscroptic GATHERING A VENOMOUS HERD / (The Pulse of Annihilation – 2026) / #technicaldeathmetal / #Tasmania #Australia #AussieMetal / “They got a Wiki page, that's saying something…”/ Tasmania, Australia (“Yeah…”) / “How any albums do they have?” / “Let's go through the album titles…”/  “You wanna watch a video?”/ #youwatchamovie / ARCHITECTS OF EXTINCTION /  “Those guys are re-tah-diculous!” / The reaction of laughter to unbelievable riffs and technical prowess   (18:18): “So here's what we've got to contend with…I'm gonna ask you, right here in front of everybody…” / “You think God listens to this podcast, dude?”/ “I wanna do a little birthday squig in the beginning…”/ “This year marks the 25th anniversary of Pig Destroyer's Prowler In The Yard, which is like the Reign In Blood of grindcore…”/ “I've got a kink now, where I can't get off unless Stephen Hawking is watching…”/ “I hate this so bad…”/ “This is beautiful…this is art.” /  #PigDestroyer JENNIFER/CHEERLEADER CORPSES (Prowler In The Yard – 2001) /  #TwentyFifthAnniversary #ProwlerInTheYard / “Oh, I farted…”/ “A little bit of WHAT?” / PISS ANGEL / “Is that better or worse?”/ “Should we start calling birthdays anniversaries instead of birthdays?”   (24:00): #TheDocket METAL NERDERY PODCAST PRESENTS: ANTHEMS / “It's gotta be bolth…” / #rockanthems #heavymetalanthems / “What is an anthem? What do you think of when you hear the word ‘anthem' (if it's metal or rock)?”/ “Everybody knows it…it gets people fired up…”/ “When the band plays the song where you all become a part of the show…that's the sing along…”/ “What is the first anthem you can think of?” /  “Everybody knows it…it's the one that your grandmother has heard…it's the non-deep cut…”/ “What would Van Halen's anthem be?”/ #BetterOffDead /  “What would AC/DC's anthem be?”/ “AC/DC's kind of an anthem band…they have at least one on every album…”/ “Did we just unlock a new dimension here?” (30:06): “What's a Zeppelin anthem?” / “We're all humans, who cares?”/ #markthetime /  “Anthems are one of those things…if you hear it at a public place like in a bar, a restaurant, or even at the grocery store…”/ “Cart…buggy…”/ “You can't NOT like it…even if you're a #Rush super deep cut fan…”/ #BlackSabbath WAR PIGS (Paranoid – 1970) /  “Now we're smiling, all of a sudden…”/ “I don't know if you've ever heard this before…about that song…those first few words…it almost has a country vibe to it…the vocal…”/  “They put the Eventide voice machines on him…”/ “All the guitar nerds will get that…”/  “What's an Eventide? Is that like a dildo or something? What do you do with that?”/  “What about Ozzy anthems?”   (38:48): #Motorhead ACE OF SPADES (Ace Of Spades – 1980) / “This is one of the most metal parts, evah!”/ “If your doctor doesn't recommend metal to you as a lifestyle improvement and a medical treatment, find a different doctor.”/ “Was the Van Hagar more anthem-y than the Roth era?” / “Yeah…you've got to, with the hairdryer and the whole thing…you don't remember the video?” / #hairdryerASMR / “Soooo…for metal bands…”/  #IronMaiden THE NUMBER OF THE BEAST (The Number Of The Beast – 1982) / “Everybody in America is like: ‘You went to the pub and got pissed off? What's wrong with you?' / “I've got one…”/ #QuietRiot METAL HEALTH (Metal Health – 1983) / “Assgrinder?”/ “That's a sing-along…”/ “Which do you think was bigger?” / “I think that's what possibly killed Twisted Sister…”/ #TwistedSister I WANNA ROCK (Stay Hungry – 1984) / #No / “How much fun was that?” / “Every band probably has their own anthem…”/ “Testament, what would be theirs?” / “For the mainstream customer…but for their fans, it would be…”/  “It is a weird anthem…that's probably one of their encores…” (51:55): “Everybody knows the Pantera one…”/ “At a bar, at a party, at a friend's house…if I hear it in a public place…I'm not complaining…I'm cool with that.”/ “It still feels like it belongs to you…”/ “Do you feel like they (Metallica) are almost in the AC/DC bucket?” / “Does your grandmother know Dyer's Eve?” / “What's Creed's anthem?”/  #Pantera COWBOYS FROM HELL (Cowboys From Hell – 1990) / “I wanna hear THAT at my grocery store, when I'm going for the meat section…”/ #markthetime / “Fun and anthems kinda go together…”/ “I don't NOT like ‘Walk'…” (58:58): “I got another one for us metal heads…”/ #StormtroopersOfDeath MARCH OF THE S.O.D. (Speak English Or Die – 1985) / “Does #Anthrax have an anthem?” / “Okay, so how about Priest?” / #abigone / “Let me know if you think this is THEIR anthem…it's gotta be…”/  “THIS FRIDAY!” / #keepitin / “That was awesome…”/ #KoRn BLIND (KoRn – 1994) / “That's gotta be, right?” / “Are you ready!?” / “This Friday…are you ready?”  (1:04:00): “What is the most recent rock or metal anthem you can think of?” /  “Has everybody lost their ability to do anthems?”/ “The anthem is the call to arms…”/  “Here's my answer to that question…in my opinion…”/ “See, I thought that was Cake…” / #TheWhiteStripes SEVEN NATION ARMY (Elephant – 2003) / “I'll take the bottom off?” /  “What's the band that everybody fucks with…everybody hates on them…?”/ “Nickelback has some anthems, for sure…now that you mention it, maybe not…”/ “That's how I clap, by the way…”/ THANK YOU FOR JOINING US!!! / #untilthenext #outroreel

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!Articles discussed:Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870 Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-TrialsPredictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyteMezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506

Two recent studies have shown remarkable advances in HIV cure research: (1) a Norwegian man who achieved long-term HIV remission after a stem cell transplant from his brother and (2) a Phase 1 trial testing CAR-T cell therapy. On this episode, Antonio Urbina, MD, Medical Director for CEI's HIV Primary Care and Prevention Center of Excellence, dives into these studies and puts them into clinical context, including how to discuss cure research with patients. Related Content: CEI Line: 1-866-637-2342  https://ceitraining.org/ Clinicaltrials.gov

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Krissy Dilger of SRNA welcomed University of Washington neuroimmunologist Dr. Shuvro Roy for an open Q&A on transverse myelitis (TM). Dr. Roy explained how TM can be both a presentation and a diagnosis, with “idiopathic TM” used when extensive testing finds no underlying cause and noted that recurrence should prompt reevaluation for conditions like NMOSD, MOGAD, or neurosarcoidosis and consideration of preventive immunotherapy [00:06:16]. He addressed audience questions about lifestyle and rehabilitation topics including diet, metabolic health, exercise, sleep issues, and safe considerations around CBD or THC-containing gummies, and reviewed approaches to chronic pain, spasticity, physical therapy timelines, and spinal cord stimulation (including ArcX) [00:13:20]. Dr. Roy also discussed the current status of peptides and stem cells, highlighted emerging cell-based therapies like CAR-T, and answered a case question about a high MOG antibody titer and its diagnostic implications [00:24:53].Shuvro Roy, MD is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a specific focus on multiple sclerosis (MS) and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune disorders. He is also a core teaching faculty member for the UW Medicine Multiple Sclerosis Center's fellowship program, contributing to clinical education and research initiatives like the ECHO MS program in collaboration with the National MS Society. Dr. Roy is actively engaged in projects aimed at improving access to care, addressing healthcare disparities, and enhancing patient safety for individuals living with MS and related conditions. He has co-authored recent research articles in medical journals on a variety of topics, including studies on stiff person syndrome, encephalomyelitis, MOG-antibody disorder, and multiple sclerosis treatment protocols. Dr. Roy is dedicated to helping his patients thrive amid challenging, lifelong neurological conditions.00:00:00 Welcome and Introductions00:01:24 What Is Transverse Myelitis00:03:30 Common Causes and Mechanisms00:06:16 Diagnosis Versus Presentation00:10:39 Monophasic or Recurrent00:13:20 Diet Do's and Don'ts00:17:25 Aging and Long-Term Health00:24:53 Peptides and Stem Cells00:33:07 Fatigue Sleep and CBD or THC-containing gummies00:37:58 Chronic Pain Options00:43:55 Physical Therapy Recovery00:47:56 Spinal Cord Stimulation ArcX00:51:46 Stopping Pregabalin Safely00:52:59 Trials and Rehab at Any Age00:56:00 MOG Titer and Diagnosis01:00:02 Closing

A New Zealand blood cancer patient who was forced to leave his children behind and make a last chance dash to Australia to access funded drugs has now been given a cutting edge transplant that is not publicly available here. Tawhai Reti, who has myeloma, had exhausted all treatment options in NZ. Earlier this year he moved to Australia without his family to access the lifesaving drug Daratumamab, which isn't funded here. It worked so well he has now been given CAR-T cell therapy, which could put him into remission indefinitely. Tawhai and Lani Reti spoke to Lisa Owen.

Organização Internacional do Trabalho, OIT, afirma que 138 milhões de crianças trabalham no mundo; diretor-geral da entidade diz que avanços demonstram que é possível erradicar o trabalho infantil, mas que ele ainda está longe do fim; Dia Mundial de Combate ao Trabalho Infantil é marcado neste 12 de junho.

summaryDr. Debbie Ozment explores how ultra-processed foods and additives like emulsifiers impact gut health, emphasizing the importance of discerning ingredient labels to promote vitality and overall well-being.keywordsgut health, ultra-processed foods, emulsifiers, CMC, polysorbate 80, gut microbiome, health tips, food labels, vitality, inflammationkey topicsImpact of ultra-processed foods on gut healthRole of emulsifiers like CMC and P80 in gut inflammationHow to read food labels for better health choicesDisclaimer: This podcast is for general information and entertainment purposes only and does not constitute medical or dental advice. Any mention of products, services, tests, or supplements is not an endorsement and may include affiliate links. Guest views are their own and may not reflect the views of Dr. Debbie Ozment or this podcast. Always consult a qualified healthcare professional for advice specific to your situation.Visit my website DrDebbieOzment.com for valuable free downloads.  Additionally,  you will find shopping links which I have curated on the website.  Please follow me on instagram at drdebbieozment.

What actually happens at a major international medical conference — and why should patients care? In this episode of The Health Advocates, Steven Newmark reports from EULAR 2026 in London, one of the world’s largest rheumatology conferences, to explain how meetings like this help shape the future of patient care. The episode explores why conferences matter not just for doctors and researchers, but for patients and advocacy organizations as well. Steven discusses how practicing clinicians learn about the latest medical advances, how researchers connect directly with physicians treating patients every day, and why organizations like GHLF play an important role in bringing real-world patient experiences into scientific and medical conversations. The episode also highlights several emerging themes already generating excitement at EULAR this year, including the growing role of artificial intelligence in rheumatology and the potential future of CAR-T and cell therapies for autoimmune diseases like lupus and rheumatoid arthritis. Most importantly, the conversation explains how scientific innovation ultimately connects back to what matters most: improving the daily lives of patients. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Amelia Violet Prouse, Associate Podcast & Video Producer at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel. See omnystudio.com/listener for privacy information.

Send us Fan MailPrime Day isn't just about massive discounts, it's about margin protection and long-term audience building. In this video, we break down why a "Low-Discount" strategy often yields higher net profit and how to use technical tools like Amazon Marketing Cloud (AMC) and Brand Tailored Promotions to capture sales after the event ends.Get help from My Amazon Guy to grow your Amazon sales. https://bit.ly/4jMZtxu#AmazonPrimeDay #AmazonFBA #AmazonSellers #AmazonPPC #amazonmarketing Want free resources? Dowload our Free Amazon guides here:Amazon Receiving Delay Guide: https://hubs.ly/Q04cdD4c0Amazon Catalog Spring Cleaning: https://hubs.ly/Q046BVfp0Amazon Proft Margin Defense 2026: https://hubs.ly/Q042trRH0Amazon SEO Toolkit 2026: https://bit.ly/4oC2ClTAmazon Seller Strategy Report 2026: https://bit.ly/3YN1RME2026 Ecommerce Website & SEO Readiness Checklist: https://hubs.ly/Q04btghf0Amazon 2026 PPC guide: https://bit.ly/4lF0OYXTimestamps00:00 Should You Actually Discount on Prime Day? 01:21 The "Added to Cart" Secret Tactic 02:54 Why the Account-Wide View is Killing Your Profit 03:55 Testing Campaigns Before the Big Event 04:12 AMC Audience Insights: Building Your Post-Prime Funnel 05:00 Summary & Next Steps for Your Brand-----------------------------------------------------------------------------------------Follow us:LinkedIn: https://www.linkedin.com/company/28605816/Instagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Twitter: https://twitter.com/myamazonguySubscribe to the My Amazon Guy podcast: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

durée : 00:51:59 - Les informés de franceinfo - Tous les soirs, les informés de franceinfo débattent de l'actualité autour de Victor Matet. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.See omnystudio.com/listener for privacy information.

Today, we're putting The Tonearm's needle on Stephen Emmer, a Dutch composer and musician based in Amsterdam. Stephen came up in the late 70s post-punk underground, and his band Minny Pops was the first international act signed to Factory Records. He is a curious genre-explorer who has worked with Lou Reed, Chaka Khan, Tony Visconti, Trevor Horn, Flood, and many others.His latest album, Asymmetrical Dot, is a chamber work rooted in his Dutch-Indonesian heritage, built around sustained tones, wordless vocals, vibraphone, and strings. The record came out of a year when his mother died, and his first grandson was born, and the contracting themes of grief and arrival appear throughout the work.We cover the album, his hearing loss, and why he walked away from commercial work to make the most personal music of his career.(The musical excerpts heard in the interview are from Stephen Emmer's Asymmetrical Dot)—Dig Deeper• Artist and Albums:Visit Stephen Emmer at stephenemmer.com and follow him on Bluesky, Instagram, and YouTubePurchase Stephen Emmer's album Asymmetrical Dot from Bandcamp or Qobuz and listen on your streaming platform of choiceThe two previous installments in the 'introspective trilogy': Maison Melody (2020) and Mt. Mundane (2024)• Key Collaborators:Tony Visconti — Producer of Recitement; longtime producer of David BowieBeth Hirsch — Vocalist and co-writer on Asymmetrical Dot, Track 5; best known for AIR's Moon SafariFernando Aponte — Grammy-winning mixing engineer, HoustonEverton Nelson — Concertmaster and violinist; has performed with the LSO, BBC Concert Orchestra, and on recordings for Radiohead, U2, and Paul McCartneyPatricia Sullivan — Mastering engineer at Bernie Grundman Mastering, Los Angeles• *Recitement* and Its Voices:Recitement — Emmer's 2007 spoken-word album, produced by Tony Visconti.Ken Nordine — Voice-over artist and "Word Jazz" pioneer; voiced "Absolutely Grey" on RecitementColors — Ken Nordine's 1966 album, originally commissioned as radio spots for the Fuller Paint CompanyLou Reed — Rock musician and poet; voiced "Passengers" on RecitementAllen Ginsberg — Beat poet; voiced "Disconnected" on RecitementRichard Burton — Welsh actor; voiced "The Leaden Echo" and "Boy with a Cart" on Recitement• Musical Influences and References:Gamelan — Traditional Indonesian percussion ensemble; central to the sonic concept of Asymmetrical DotDave Brubeck — American jazz pianist; one of the first musicians Emmer heard as a child, via his mother's ballet teachingHeitor Villa-Lobos — Brazilian composer; among the diverse influences Emmer's mother brought to her ballet classesClaude Debussy and Gamelan — Referenced by Emmer as a historical predecessor in integrating gamelan into Western composition• Contextual References:Holiday on Ice — International touring ice show for which Emmer served as music directorMotörhead — British heavy metal band; Emmer's hearing damage traces to a backstage encounter with their sound systemCharles Ives — American modernist composer who ran a successful insurance business alongside his musical career; referenced in the episode's discussion of portfolio careersAmbon, Indonesia — Island in the Maluku province of Indonesia, historically known as Amboina; birthplace of Emmer's mother and inspiration for the album's track "Amboina (for Roekie Aronds)"—Dig into this episode's complete show notes at podcast.thetonearm.com—• Did you enjoy this episode? Please share it with a friend! You can also rate The Tonearm ⭐️⭐️⭐️⭐️⭐️ and leave a review on Apple Podcasts. • Subscribe! Be the first to check out each new episode of The Tonearm in your podcast app of choice. • Looking for more? Visit podcast.thetonearm.com for bonus content, web-only interviews + features, and the Talk Of The Tonearm email newsletter. You can also follow us on Bluesky, Mastodon, YouTube, and LinkedIn. • Be sure to bookmark our online magazine, The Tonearm! → thetonearm.com Hosted on Acast. See acast.com/privacy for more information.

That chair in your online cart is way over budget. But there's a trick to help you snag discounts off at checkout. And Johanna was moving to Spain with a new baby and a house full of furniture to sell. Fed up with scammers on Facebook Marketplace, she used AI to make her own selling site. Zero coding experience. Learn more about your ad choices. Visit megaphone.fm/adchoices

They also explore exciting new therapies like CAR T-cell treatment, along with practical advice on self-advocacy, building the right healthcare team, and what it truly means to thrive while living with a rheumatic disease. Episode at a glance: Why Dr. Singh became a rheumatologist after watching her grandmother struggle with osteoarthritis What current research shows about biologics and cancer risk Why most cancer fears surrounding arthritis medications are often more complicated than they seem How cancer immunotherapy can sometimes trigger inflammatory arthritis The importance of communication between rheumatologists, oncologists, and other specialists What patients should know about skin cancer, lymphoma, and other cancer risks The emerging role of CAR-T cell therapy in autoimmune diseases Why researchers are increasingly optimistic about long-term remission and potential cures Advice for newly diagnosed patients navigating inflammatory arthritis What it means to truly "thrive" while living with rheumatic disease Medical disclaimer:  All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, we discuss left atrial appendage closure for atrial fibrillation, oxygen strategies in respiratory failure, an all-oral treatment for acute myeloid leukemia, CAR T-cell therapy enabling kidney transplantation, and a case of a neuroepithelial tumor that developed after gene therapy. We review childhood vaccine hesitancy, follow a complex diagnostic case, and examine Perspectives on corporatization in medicine, famine and war, and the future of health care systems.

Rob explains why he missed the bonus show. Which golf predictions came true? Rob has new golf rival, Frank from Myrtle Beach. Justin took Gavin skeet shooting. One of them is awful. Joe calls Jackson about the house's water quality. 

In this week's Omni Talk Retail Fast Five sponsored by the A&M Consumer and Retail Group, Mirakl, Ocampo Capital, Quorso and Veloq, Chris Walton and special guest Shelley Huff, former CEO of Serta Simmons Bedding and co-founder of The Interval, discussed: • Google unveiling its new Universal Cart that allows shoppers to add products across retailers and channels into a single AI-powered shopping experience, and whether it represents the biggest long-term threat yet to Amazon's commerce dominance: https://www.retaildive.com/news/google-launches-cross-retailer-universal-cart/820957/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-26%20Retail%20Dive%20Newsletter%20%5Bissue:85275%5D&utm_term=Retail%20Dive • Walmart rolling out a new prepaid consolidation program that simplifies inbound logistics for suppliers, and why both Chris and Shelley see it as a rare win-win for retailers and vendors alike: https://www.supplychaindive.com/news/walmart-rolling-out-simplified-inbound-logistics-for-suppliers/821111/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-27%20Supply%20Chain%20Dive%20%5Bissue:85359%5D&utm_term=Supply%20Chain%20Dive • SPAR Austria expanding its use of inventory robots to additional stores, and what the move signals about the growing role of robotics in improving store operations and inventory accuracy: https://spar-international.com/news/spar-austria-expands-inventory-robot-trial/ • Walmart reporting explosive growth in store-fulfilled delivery, including record-fast delivery times and surging drone deliveries, and which metrics matter most as the company battles Amazon for customer loyalty: https://www.supplychaindive.com/news/walmart-store-fulfilled-deliveries-getting-faster/821126/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-28%20Supply%20Chain%20Dive%20%5Bissue:85420%5D&utm_term=Supply%20Chain%20Dive • AWS launching a new agentic shopping assistant solution that allows retailers to deploy Amazon-powered conversational shopping experiences, and the critical question every retailer must answer about who owns the customer intelligence layer: https://www.aboutamazon.com/news/aws/aws-agentic-shopping-assistant-retailers And RADAR CEO Spencer Hewett also dropped by for 5 Insightful Minutes to discuss his company's $170 million raise, connected stores at scale, and why real-time retail is finally becoming a reality. There's all that, plus sunrise hikes in Arizona, European grocery innovation, The Rock's latest product launch, and why younger shoppers may be more comfortable letting AI make decisions for them. P.S. Be sure to check out all our other podcasts from the past week here, too: https://omnitalk.blog/category/podcast/ P.P.S. Also be sure to check out our podcast rankings on Feedspot: https://podcasts.feedspot.com/retail_podcasts/ Music by hooksounds.com

In the future, can autoimmune disease become curable? A groundbreaking study from Germany suggests there may be a pathway in some cases. Patients with severe, treatment-refractory lupus who received CD19 CAR-T cell therapy have remained in drug-free remission for up to five years without ongoing immunosuppression. In this episode, we discuss how these findings are shifting the conversation from disease control to the possibility of cure, and what they could mean for lupus, inflammatory myopathies, systemic sclerosis, vasculitis, rheumatoid arthritis, and autoimmune diseases more broadly. We also explore CAR-T therapy, immune resets, regulatory T cells, relapse risk, and the future of rheumatology with Dr. Georg Schett. 

This month, the gals invite Cam Collins from Old Gods of Appalachia on the show to discuss Waffle House teleportation, a bowel movement bust, accidental nudes, a zombie rabbit, and one hell of an Easter egg. Tune in now for May's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.